Ocugen, Inc
NASDAQCM:OCGN
United States / Healthcare / Biotechnology
OCGN News
Welcome to Your News Upgrade
Be the First to Know and Act on Market Moving News.
OCGN stock touches 52-week low at $0.52 amid market challenges
In a turbulent market environment, Ocugen Inc. (NASDAQ:OCGN) stock has reached a 52-week low, dipping to $0.52. According to InvestingPro data, the company's high beta of 3.89...
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200”a Novel Fusion Protein for Diabetic Macular Edema
OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has been approved...
Ocugen's OCU200 advances to next trial phase with safety approval
MALVERN, Pa. - Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company specializing in gene therapies for eye diseases, has received approval from the Data and Safety Monitoring Board...
Ocugen : Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema
Ocugen (NASDAQ:OCGN), Inc. (“Ocugen” or the “Company”) (OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Data and Safety...
Earnings call transcript: Ocugen Q4 2024 beats earnings forecast
Ocugen, Inc. (OCGN) reported its Q4 2024 earnings, showing a narrower-than-expected net loss and outperforming revenue forecasts. The company's EPS stood at -$0.05, surpassing the...
Ocugen earnings beat, revenue topped estimates
Investing.com - Ocugen (NASDAQ: OCGN) reported first quarter EPS of $-0.050, better than the analyst estimate of $-0.060. Revenue for the quarter came in at $760K versus the...
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ETReached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially...
Ocugen stock hits 52-week low at $0.6 amid market challenges
In a challenging market environment, Ocugen Inc. (NASDAQ:OCGN) stock has touched a 52-week low, dipping to $0.6. According to InvestingPro data, the company maintains a strong...
Ocugen gains EU nod for gene therapy classifications
MALVERN, Pa. – Ocugen, Inc. (NASDAQ: NASDAQ:OCGN), a biotechnology firm specializing in gene therapies for blindness trading at $0.65 per share, has received a positive...
Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for St
Ocugen (NASDAQ:OCGN), Inc. (Ocugen or the Company) (OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the European Commission...